



Cancer 2015 - 2017: NQF-Endorsed® Maintenance Standards Under Review

Click the measure numbers to read more about the measure on QPS!

Measure Number	Title	Description	Measure Steward
0219	Post breast conservation surgery irradiation	Percentage of female patients, age 18-69, who have their first diagnosis of breast cancer (epithelial malignancy), at AJCC stage I, II, or III, receiving breast conserving surgery who receive radiation therapy within 1 year (365 days) of diagnosis.	Commission on Cancer, American College of Surgeons
0220	Adjuvant hormonal therapy	Percentage of female patients, age >18 at diagnosis, who have their first diagnosis of breast cancer (epithelial malignancy), at AJCC stage T1cN0M0,IB to III, who's primary tumor is progesterone or estrogen receptor positive recommended for tamoxifen or third generation aromatase inhibitor (considered or administered) within 1 year (365 days) of diagnosis.	Commission on Cancer, American College of Surgeons
0221	Image or palpation-guided needle biopsy (core or FNA) of the primary site is performed to establish diagnosis of breast cancer	Percentage of patients presenting with AJCC Stage Group 0, I, II, or III disease, who undergo a needle biopsy to establish diagnosis of breast cancer.	Commission on Cancer, American College of Surgeons
0223	Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer	Percentage of patients under the age of 80 with AJCC III (lymph node positive) colon cancer for whom adjuvant chemotherapy is considered and not received or administered within 4 months (120 days) of diagnosis.	Commission on Cancer, American College of Surgeons
0225	At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.	Percentage of patients >18yrs of age, who have primary colon tumors (epithelial malignancies only), at AJCC stage I, II or III who have at least 12 regional lymph nodes removed and pathologically examined for resected colon cancer.	Commission on Cancer, American College of Surgeons

Measure Number	Title	Description	Measure Steward
0377	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) or an acute leukemia who had baseline cytogenetic testing performed on bone marrow	American Society of Hematology
0378	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy with documentation of iron stores within 60 days prior to initiating erythropoietin therapy	American Society of Hematology
0389	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer	American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)
0390	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH [gonadotropin-releasing hormone] agonist or antagonist)	American Urological Association (AUA)
0455	Recording of Clinical Stage Prior to Surgery for Lung Cancer or Esophageal Cancer Resection	Percentage of surgical patients aged 18 years and older undergoing resection for lung or esophageal cancer who had clinical staging provided prior to surgery	The Society of Thoracic Surgeons
0457	Recording of Performance Status prior to Lung or Esophageal Cancer Resection	Percentage of surgical patients aged 18 years and older undergoing resection for lung or esophageal cancer who had their performance status recorded within two weeks prior to the surgery date	The Society of Thoracic Surgeons
0459	Risk-Adjusted Morbidity: Length of Stay >14 Days After Elective Lobectomy for Lung Cancer	Percentage of patients aged 18 years and older undergoing elective lobectomy for lung cancer who had a prolonged length of stay >14 days	The Society of Thoracic Surgeons

Measure Number	Title	Description	Measure Steward
0460	Risk-Adjusted Morbidity and Mortality for Esophagectomy for Cancer	Percentage of patients aged 18 years and older undergoing elective esophagectomy for esophageal cancer who developed any of the following postoperative conditions: bleeding requiring reoperation, anastomosis leak requiring medical or surgical treatment, reintubation, ventilation >48 hours, pneumonia, or discharge mortality	The Society of Thoracic Surgeons
0508	Diagnostic Imaging: Inappropriate Use of “Probably Benign” Assessment Category in Screening Mammograms	Percentage of final reports for screening mammograms that are classified as “probably benign”	American College of Radiology (ACR)
0509	Diagnostic Imaging: Reminder System for Screening Mammograms	Percentage of patients undergoing a screening mammogram whose information is entered into a reminder system with a target due date for the next mammogram	American College of Radiology (ACR)
0559	C0559: Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB - III hormone receptor negative breast cancer.	Percentage of female patients, age >18 at diagnosis, who have their first diagnosis of breast cancer (epithelial malignancy), at AJCC stage T1cN0M0, or Stage IB -III, who's primary tumor is progesterone and estrogen receptor negative recommended for multiagent chemotherapy (considered or administered) within 4 months (120 days) of diagnosis.	Commission on Cancer, American College of Surgeons
0562	Overutilization of Imaging Studies in Melanoma	Percentage of patients, regardless of age, with a current diagnosis of Stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period, for whom no diagnostic imaging studies were ordered	American Academy of Dermatology
0650	Melanoma: Continuity of Care – Recall System	Percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within a 12 month reporting period, into a recall system that includes: <ul style="list-style-type: none"> • A target date for the next complete physical skin exam , AND • A process to follow up with patients who either did not make an appointment within the specified timeframe or who missed a scheduled appointment 	American Academy of Dermatology

Measure Number	Title	Description	Measure Steward
1857	Patients with breast cancer and negative or undocumented human epidermal growth factor receptor 2 (HER2) status who are spared treatment with trastuzumab	Percentage of adult patients (aged 18 or over) with invasive breast cancer that is HER2/neu negative who are not administered trastuzumab	American Society of Clinical Oncology
1858	Trastuzumab administered to patients with AJCC stage I (T1c) – III and human epidermal growth factor receptor 2 (HER2) positive breast cancer who receive adjuvant chemotherapy	Percentage of adult patients (aged 18 or over) with invasive breast cancer that is HER2/neu positive who are administered trastuzumab	American Society of Clinical Oncology
1878	Human epidermal growth factor receptor 2 (HER2) testing in breast cancer	Percentage of adult patients (aged 18 or over) with invasive breast cancer who receive human epidermal growth factor receptor 2 (HER2) testing	American Society of Clinical Oncology